Cytel to acquire SDS Life Science and SDS MedteQ

The move will add new global talent to Cytel’s Strategic Consulting group

Piramal Pharma Solutions launches ADCelerate

ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission

Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer

Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms

Charsire's new drug aims to capture dementia treatment market

Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease

Quinten Health closes its financing round to advance disease modeling platforms

Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.

Parexel appoints Peyton Howell and Amy McKee

These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.

Infosys completes acquisition of BASE life science

The acquisition reaffirms Infosys’ commitment to help global life sciences companies